AbbVie (ABBV.US) intends to submit a regulatory application for Rinvoq alopecia areata therapy to achieve major late-stage clinical endpoints.

Zhitong Finance APP learned that AbbVie (ABBV.US) announced on Thursday that its developed alopecia treatment drug Rinvoq (upadacitinib) has achieved primary goals in two key late-stage trials. The trials tested two dosing regimens of 15 mg and 30 mg daily, the results showed that after 24 weeks of treatment, 45.2% of patients in the 15 mg group achieved at least 80% regrowth of scalp hair, while this proportion increased to 55% in the 30 mg group, compared to only 1.5% of patients in the placebo group achieving similar results.